G
Gerhard Zugmaier
Researcher at Amgen
Publications - 155
Citations - 11420
Gerhard Zugmaier is an academic researcher from Amgen. The author has contributed to research in topics: Blinatumomab & Minimal residual disease. The author has an hindex of 39, co-authored 141 publications receiving 9561 citations. Previous affiliations of Gerhard Zugmaier include National Institutes of Health & Georgetown University Medical Center.
Papers
More filters
Journal ArticleDOI
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf C. Bargou,Eugen Leo,Gerhard Zugmaier,Matthias Klinger,Mariele Goebeler,Stefan Knop,Richard Noppeney,Andreas Viardot,Georg Hess,Martin Schuler,Hermann Einsele,Christian Brandl,Andreas Wolf,Petra Kirchinger,Petra Klappers,Margit Schmidt,Gert Riethmüller,Carsten Reinhardt,Patrick A. Baeuerle,Peter Kufer +19 more
TL;DR: The clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells, is reported on.
Journal ArticleDOI
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Max S. Topp,Nicola Gökbuget,Anthony S. Stein,Gerhard Zugmaier,Susan O'Brien,Ralf C. Bargou,Hervé Dombret,Adele K. Fielding,Leonard T. Heffner,Richard A. Larson,Svenja Neumann,Robin Foà,Mark R. Litzow,Josep-Maria Ribera,Alessandro Rambaldi,Gary J. Schiller,Monika Brüggemann,Heinz A. Horst,Chris Holland,Catherine Jia,Tapan Maniar,Birgit Huber,Dirk Nagorsen,Stephen J. Forman,Hagop M. Kantarjian +24 more
TL;DR: Single-agent blinatumomab showed antileukaemia activity in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia characterised by negative prognostic factors.
Journal ArticleDOI
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp,Peter Kufer,Nicola Gökbuget,Mariele Goebeler,Matthias Klinger,Svenja Neumann,Heinz-A. Horst,Thorsten Raff,Andreas Viardot,Mathias Schmid,Matthias Stelljes,Markus Schaich,Evelyn Degenhard,Rudolf Köhne-Volland,Monika Brüggemann,Oliver G. Ottmann,Heike Pfeifer,Thomas Burmeister,Dirk Nagorsen,Margit Schmidt,Ralf Lutterbuese,Carsten Reinhardt,Patrick A. Baeuerle,Michael Kneba,Hermann Einsele,Gert Riethmüller,Dieter Hoelzer,Gerhard Zugmaier,Ralf C. Bargou +28 more
TL;DR: T cells engaged by blinatumomab seem capable of eradicating chemotherapy-resistant tumor cells that otherwise cause clinical relapse in patients with MRD-positive B-lineage ALL after intensive chemotherapy.
Journal ArticleDOI
Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.
Erik W. Thompson,Soonmyoung Paik,Nils Brünner,Connie L. Sommers,Gerhard Zugmaier,Robert Clarke,Thomas B. Shima,Jeffrey A. Torri,Steven Donahue,Marc E. Lippman,George R. Martin,George R. Martin,Robert B. Dickson +12 more
TL;DR: Data from these cell lines suggest that human breast cancer progression results first in the loss of ER, and subsequently in VIM acquisition, the latter being associated with increased metastatic potential through enhanced invasiveness.
Journal ArticleDOI
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Gökbuget,Hervé Dombret,Massimiliano Bonifacio,Albrecht Reichle,Carlos Graux,Christoph Faul,H. Diedrich,Max S. Topp,Monika Brüggemann,Heinz-August Horst,Violaine Havelange,Julia Stieglmaier,Hendrik Wessels,Vincent Haddad,Jonathan Benjamin,Gerhard Zugmaier,Dirk Nagorsen,Ralf C. Bargou +17 more
TL;DR: After treatment with blinatumomab in a population of patients with MRd-positive B-cell precursor ALL, a majority achieved a complete MRD response, which was associated with significantly longer RFS and OS compared with MRD nonresponders.